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Human immunodeficiency virus (HIV) infection is epidemic among intravenous drug users
(IVDU), particularly in the northeastern United States. IVDU are playing a critical role in the
spread of HIV by infecting their heterosexual partners and children, as well as their needle-
sharing partners. The epidemiology of HIV infection among IVDU is reviewed here, including a
compilation of seroprevalence data. Relevant determinants of the future spread of HIV among
IVDU are discussed, including the major risk factors for HIV seropositivity, the modes of HIV
transmission, and aspects of the natural history of HIV infection in IVDU. The public health
policy implications of these issues include the need for education of adolescents and the general
public about the risks of drug injection and heterosexual intercourse with IVDU, as well as
motivation of IVDU to stop injecting, never share injection paraphernalia, or, at least, clean
needles effectively.
INTRODUCTION
Infection with the human immunodeficiency virus, type 1 (HIV-1; also called
HTLV-III, LAV-1, and ARV; referred to here as HIV), the etiologic agent of the
acquired immunodeficiency syndrome (AIDS), is epidemic among certain segments of
the United States population, including intravenous drug users (IVDU). The propor-
tions ofthe total of31,381 reported AIDS cases in theU.S. attributed to the two major
transmission categories, male homosexual activity and intravenous (IV) drug use, have
remained constant over the past few years at 66 percent and 17 percent, respectively
[1]. In Connecticut, however, newly diagnosed AIDS cases are now predominantly
relaed to IV drug use [2].
In Connecticut, as well as in New York and New Jersey, the percentage of AIDS
cases involving IV drug use has been steadily increasing over the past few years.
Thirty-eight percent ofthe AIDS cases reported in Connecticut in 1986 were in IVDU
and an additional 4 percent were in IVDU who were also homosexual/bisexual males;
only 40 percent of the Connecticut AIDS cases reported in 1986 were among those
whose only risk for acquiring HIV was a homosexual/bisexual sexual orientation [2].
New Haven, Connecticut, has the highest cumulative incidence rate of AIDS cases
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among Connecticut cities and towns. About 60 percent ofthe 90 reported AIDS cases
in the city of New Haven have been associated with heterosexual intravenous drug
abuse [3]. These persons have been either IVDU, heterosexual partners of IVDU, or
infant children of IVDU [3]. The cumulative incidence of AIDS in the city of New
Haven (68/100,000) is still modest compared to the highest incidence areas ofthe city
ofSan Franciso (316/100,000), western Palm Beach County, Florida (295/100,000),
and the borough of Manhattan (270/100,000) [4]. The currently increasing HIV
seroprevalence in New Haven, and the experiences in areas wherethe HIV epidemic is
more advanced among IVDU (such as New York City and several European cities,
discussed later), however, lead to gloomy predictions of a steadily increasing AIDS
incidence in New Haven in the future. Indeed, the entire urban Northeast may be a
harbinger for the evolution of this epidemic beyond, as well as among, U.S. IVDU to
those who are not now considered at increased risk for acquiring HIV.
A major public health concern is HIV transmission from IVDU totheir heterosexual
partners and children. Four percent (1,180) ofall U.S. AIDS cases (2 percent ofmales
with AIDS and 27 percent offemales with AIDS) have heterosexual sex partners with
AIDS or at risk for AIDS as theironly reported risk factor [1]. About 80 percentofall
such cases of presumably heterosexually transmitted AIDS in the U.S. were appar-
ently acquired by heterosexual contact with IVDU, predominantly from male-
to-female transmission. In Connecticut, 65 percent (13/20) of such presumably
heterosexually acquired AIDS cases were apparently transmitted from IVDU [2].
Accurate seroprevalence surveys in the general U.S. population have not yet been
done, so it is currently impossible to assess how rapidly HIV infection might spread in
the U.S. through heterosexual activity.
Only two large-scale HIV seroprevalence studies ofgroups not considered to include
persons in currently recognized HIV transmission categories have been reported in the
U.S. Nationwide, only 0.04 percent of voluntary blood donors were WB (Western
blot)-confirmed seropositives [5]. Among military recruit applicants [6], however,
there was greater geographic and racial variation in HIV seroprevalence, with rates of
about 1 percent among the oldest, non-white recruit applicants from Mid-Atlantic
states (including New York and New Jersey). It remains unclear how many of the
military recruit applicants studied were IVDU and/or homosexual/bisexual males
[6].
The epidemiology ofpediatric AIDS is also closely linked to IVDU. Eighty percent
(362/453) of the U.S. pediatric AIDS cases were acquired perinatally in families
where one or both parents had a risk factor for AIDS [1], largely parenteral drug use.
Most of these cases of apparently maternally transmitted pediatric AIDS are from
New York City, where 84 percent ofthe known children with AIDS have one or both
parents who are IVDU [7]. In New Haven, 87 percent ofthe 23 symptomatic cases of
HIV infection in children have occurred in families where the mother or her sexual
partner were IVDU [8]. Estimates are made that at least 500 HIV-infected infants are
now born annually in New York City alone [7].
Despite the deadly reality and alarming potential ofepidemic HIV infection among
IVDU, thorough epidemiologic study has been limited by the isolated and stigmatized
nature ofthe IVDU subculture. After reviewing the epidemiology and natural history
of HIV infection among IVDU worldwide, including preliminary data from our
ongoing studies in Connecticut and data presented at the International Conferences on
AIDS in 1985 and 1986, the public health policy implications ofthis information will
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be discussed. Emphasis will be placed on the factors that are most relevant in
determining the degree to which HIV will spread in the future-prevalence of
infection, sexual and drug use behaviors responsible for HIV transmission, and the role
ofcofactors in susceptibility to and outcome of HIV infection.
SERO-EPIDEMIOLOGY
The prevalence of HIV infection among those who use intravenous drugs has been
estimated in the U.S. at between 5-75 percent with an annual incidence of 1-10
percent [9]. Estimates ofthe size ofthe total population at risk for HIV infection from
intravenous drug use remain incomplete because of difficulties in defining and
studying this population. There are also uncertainties about the nature and extent of
the practice of different individuals re-using injection equipment ("needle sharing")
which presumably underlies HIV transmission among IVDU. IVDU as a group are
diverse and often anonymous. Generally, IVDU are only identified when arrested or
when seeking drug abuse, psychiatric, or medical treatment. While the National
Institute on Drug Abuse estimates 350,000-400,000 active intravenous heroin users
(who self-inject largely at least daily), no precise estimates of the number of periodic
casual users of heroin ("chippers") or of intravenous cocaine and amphetamine users
are available [10]. Estimates are made, though, of 750,000 IVDU nationwide; data
suggests that there are 258,000 IVDU in New York State [11]. All the published data
on HIV infection in IVDU are currently limited to narcotic addicts.
The seroprevalence of HIV among IVDU has been studied in various groups of
IVDU as they presented to the criminal justice and/or drug treatment systems,
although all these data are biased by representing only discrete geographically and
behaviorally defined subsets of IVDU that may not have uniform risk of HIV infection.
Tables 1 through 3 list HIV seroprevalence rates-by enzyme-linked immunoassay
(EIA) with a confirmatory test such as a Western blot in most cases, as indicated-
from different groups of IVDU worldwide [12-64].
It is reasonable to posit that HIV risk among IVDU varies with the interrelated
degree of drug abuse and needle sharing, and examination of Tables 1 through 3
supports such a speculation. The "detoxification" groups (in Table 1) include
hospitalized IVDU who are "strung out" after heavy, intensive heroin abuse. These
groups may be more similar to groups of IVDU hospitalized for other reasons (such as
infections or other illnesses that are often related to unsterile injections and needle
sharing) than to those on chronic methadone maintenance programs. Those on chronic
methadone maintenance programs may still be injecting (often cocaine, rather than
heroin), but are likely to be injecting drugs less intensively (i.e., perhaps sharing
needles less) and more likely to have access to health care and AIDS risk reduction
counseling. The studies identified as "hepatitis studies" in Tables 1 through 3 may
select a subset that has active illness from another injection-acquired virus and may
therefore be more likely than average to have acquired HIV by needle sharing. Those
being admitted to methadone maintenance programs may more accurately reflect the
full gamut of the population of active IVDU in a community. Persons seeking drug
abuse treatment may, however, have a lower risk for HIV infection than those who do
not voluntarily seek to limit their self-destructive behaviors, such as prisoners.
Generally, to avoid selection bias in epidemiologic investigations and an overestimate
of HIV seroprevalence, it seems prudent to study non-hospitalized IVDU in communi-
ty-based settings.
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TABLE 1
HIV Seroprevalence Among IVDU
Location/Group % EIA + (No.) % Confirmed + (No.) [Ref] Date
New York City
Detox.*
Detox. (while on Meth. Maint.)
Detox. (first time)
Meth. Maint.**
Hosp.***
Meth. Maint.
Detox. & Meth. Maint.
Detox. & Meth. Maint.
Hosp.
Outpatient****
Meth. Maint.
Meth. Maint.
Boston
Meth. Maint. Admit.*****
New Jersey
Meth. Maint., Outpatient Drug-Free,
and Residential Treatment
New Haven
Hepatitis study
Meth. Maint. Admit.
Miami
Meth. Maint.
San Francisco
Detox. & Meth. Maint.
Meth. Maint. & other
Chicago
Washington, D.C.
87 (75/86)
72 (51/71)
51 (32/63)
57 (80/140)
59 (162/273)
47 (166/351)
75 (6/8)
25 (5/20)
9 (6/69)
58 (50/86) (RIPA-p25)
56 (14/25) (WB)
29 (9/31) (WB)
32 (141/443) (WB)
35 (36/103) (WB)
42 (29/69) (WB)
2-59 (total 745) (WB)
30 (84/283) 10 (28/283) (WB)
23 (39/171) 22 (38/171) (WB)
12 (23/186) 5 (9/186) (WB)
9 (5/53)
10 (28/284) (WB)
5 (6/128) (WB & IF)
11 (4/35)
7 (-)
New Orleans
<1 (-)
California (except San Francisco)
Meth. Maint. & other
Denver
Outpt. (Sexually transmitted disease
clinic)
0 (0/217) (WB & IF)
4 (-)
[12] 1984
[13] 1985
[13] 1985
[13] 1985
[14] 1981-82
[14] 1981-82
[15] 1985
[16] 1986
[17] 1985
[17] 1985
[18] 1985
[19] 1984-85
[20] 1982-83
[21-23] 1984
[24] 1982-83
[25] 1986
[26] 1986
[27] 1985
[13] 1985
[28] 1985
[13] 1985
[23] 1986
[23] 1986
[28] 1985
[2] 1985
Detroit
Hosp. 18 (17/96) 13 (12/96) [29] 1985-86
The groups ofIVDU studied in various locations aredescribed more fully in the text (see Seroepidemiolo-
gy, above).
*Detox.: Detoxification Program (in-hospital)
**Meth. Maint.: Methadone Maintenance Program (outpatients)
***Hosp.: Hospitalized (for reasons other than detoxification, usually infections)
****Outpt.: Outpatients
*****Meth. Maint. Admit.: Methadone Maintenance Program Admissions (outpatients)
§Confirmation ofenzyme-linked immunoassay (EIA) seropositivity by a Western blot (WB), radioimmu-
noprecipitation with p25 (RIPA-p25), immunofluorescence (IFA), or other methods was not mentioned
in the report
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GEOGRAPHY OF THE EPIDEMIC
The epidemic of HIV infection among IVDU is more advanced in New York City
than elsewhere in the U.S. The first series of reports describing AIDS in 1981-82
included one from New York City with a few cases in heterosexual male IVDU as well
as homosexual/bisexual males [65]. Reports describing AIDS cases in female IVDU
[66], among prisoners who had abused drugs [67-69], and in heterosexual IVDU
presenting to a number of general hospitals [70-72] confirmed that intravenous drug
use was a separate risk factor from homosexuality and bolstered the hypothesis that a
blood-borne transmissible agent was etiologic. All these early reports were from
metropolitan New York City, and to this date about 80 percent of the reported U.S.
AIDS cases with intravenous drug use as the primary risk factor are in the New York
City area. There has been an apparent link between New York City IVDU and
homosexual/bisexual men. In one study, most of the IVDU with AIDS or AIDS-
related complex (ARC) reported needle sharing with homosexual/bisexual men in
"shooting galleries," sites where rented needles are re-used by multiple different
IVDU [73]. While the exact origins of HIV remain obscure and it may have infected
IVDU in the U.S. as early as 1971 [74], the New York City area has the highest
reported seroprevalence among IVDU in the U.S., ranging from about 30 percent to
over 60 percent WB-confirmed HIV seropositivity in recent studies (refer to Table 1).
The geographic spread of HIV in the IVDU population has apparently been more
restricted than among homosexual/bisexual men, perhaps because of the limited
mobility imposed by withdrawal symptoms and drug-seeking behavior. In 1984, a
study of IVDU in New Jersey drug treatment programs (including methadone
maintenance, outpatient drug-free, and residential treatment programs) found
decreasing seropositivity rates with increasing distance from Manhattan ([21-23],
Table 1). Fifty-nine percent (136/231) of those within five miles of Manhattan, 45
percent (75/166) of those five to nine miles from Manhattan, 24 percent (69/287) of
those 10-35 miles from Manhattan and 1.6 percent (1/61) of those 80 miles from
Manhattan were WB-confirmed HIV seropositives [21-23]. Preliminary data from
surveillance of drug treatment program admissions in four different Connecticut
metropolitan areas in 1986-7 also show that HIV seroprevalence decreases (from 41
percent to 14 percent) with increasing distance (from 38 to 113 miles) from New York
City [25]. Theepidemic is notstrictly limited toone area, however, as evidenced by the
seroprevalence among groups ofIVDU in Boston, San Francisco, and numerous cities
in Europe, particularly in Spain, Italy, Switzerland, France, and the United Kingdom
(Tables 1-3). The epidemic may bespreading from urban centers with high prevalence
to surrounding areas. In the absence ofintervention, the pace ofsuch an expansion of
the epidemic may well increase as both the number of prevalent cases and number of
high prevalence urban centers increase.
PACE OF THE EPIDEMIC
HIV seroprevalence in IVDU in several U.S. cities appears to be quite low at present
(Table 1). If the experience in the locations where seroprevalence has been assessed
serially over time is any indication, however, the potential explosiveness of this
epidemic should not be underestimated. In New York City, New Haven, Edinburgh,
Dublin [36], Valencia, Milan, Padua, and Bari (refer to Tables 1-3) seroprevalence
has been observed to increase rapidly. In New Haven, the seroprevalence in a large,
community-based, non-hospitalized sample has more than doubled between 1982-3
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and 1986-7 to 25 percent [25], approaching the level ofinfection in theNew York City
area. The HIV seroprevalence among IVDU in drug treatment has increased in New
York City from 11 percent in 1977 to 27 percent in 1979 and to 58 percent in 1984
[75]. Even more rapid spread has been noted in some European cities. In Edinburgh,
confirmed HIV seroprevalence in two different study groups rose from 0 to more than
40 percent in two years [34,35]; in Spain [37,38] and Italy [49,50,53,54], increases
from 0 to as high as 75 percent HIV EIA seroprevalence were noted over several
years.
There are differences in frequency of needle sharing in different locations; 35
percent (122/353) reported sharing daily in New Jersey, 10 percent (21/218) reported
sharing daily in New Orleans, and 5 percent (6/128) reported sharing daily in
Washington, D.C. [23]. It is likely that HIV spreads more rapidly through the IVDU
in a community at any given prevalence level ifneedle sharing is more frequent in that
community than another. In London, for example, only 31 percent (14/45) of the
IVDU interviewed reported needle sharing within the prior three months [33], but in
Edinburgh 63 percent (49/78) reported sharing weekly, and 42 percent (33/78)
reported sharing on a daily basis [76]. This difference may account for the lower
reported seroprevalence in London compared to Edinburgh [76] and may help to
explain the dramatic difference between the two cities in the increase in HIV
seroprevalence from 1983-1985 (refer to Table 2), which suggests that large-scale
reduction in needle sharing among IVDU might slow the spread ofthe epidemic.
RISK FACTORS FOR HIV SEROPOSITIVITY
Needle Sharing
Numerous studies suggest that the risk of HIV seropositivity in IVDU is correlated
with the frequency of sharing needles [15,18,21,34,73,76] or sharing needles in a
shooting gallery [18]. This risk factor may also be indirectly reflected in total duration
of drug use, which has also been associated with seropositivity [18]. One study
explicitly confirms the hypothesis inherent in all these data that there is an increasing
risk of HIV seropositivity with increasing numbers of persons with whom needles are
shared [27].
Race/Ethnicity
In the U.S., the cumulative incidences of AIDS among blacks and Hispanics are
each over three times the rates for whites [77]. The Northeast exceeds the national
average, however; the incidences of AIDS among Connecticut blacks and Hispanics
are each nine times the rate for Connecticut whites [78]. Eighty-one percent of the
reported U.S. AIDS cases in IVDU, 72 percent of women with AIDS, and 90 percent
ofchildren with perinatally acquired pediatricAIDS areblackor Hispanic [77]. While
the proportion of AIDS patients who are black or Hispanic is greatest among those
with IV drug use as their primary risk factor, the proportion of blacks and Hispanics
with AIDS is relatively high (compared to the overall population's racial/ethnic
distribution) in all transmission categories, except hemophiliacs [77].
Indeed, HIV seroprevalence studies in the U.S. have revealed a racial/ethnic group
association with HIV seropositivity that parallels the patterns ofreported AIDS cases.
Among the military recruit applicants surveyed for HIV antibody, there was a fourfold
higher seroprevalence among the blacks compared to the whites [6]. One group of
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Location/Group
London, U.K.
Edinburgh, U.K.
Hosp.
Dublin, Ireland
Valencia, Spain
Bilbao, Spain
Barcelona, Spain
Hosp.
Madrid, Spain
Hosp.
Barcelona, Spain
Hosp.
Amsterdam, The Netherlands
Meth. Maint. Admit.
Prostitutes
Stockholm, Sweden
Zurich, Switzerland
Geneva, Switzerland
Bern, Switzerland
Munich, W. Germany
West Berlin, W. Germany
Prisoners
'Refer to footnotes ofTable 1.
TABLE 2
HIV Seroprevalence Among IVDU'
% EIA + (No.) % Confirmed + (No.)
1.5 (4/269) 1.5 (4/269) (IF)
2.5 (5/203) 2.5(5/203) (IF)
6.4 (1-5/236) (IF)
0.7 (1/146) -§
51 (83/164) (WB & IF)
0 (0/182) 1982 (WB & IF)
14 (17/124) 1983
42 (86/205) 1984
37 (66/178) 1985
0 1982 (WB)
30 (178/603) 1985
37 (112/303)
11 1,983
40 1984
48 1985
50 (239/479) 27 (131/479) (WB)
71 (R2/I I SW (IF)
56 (53
3 (5/1
23 (12
40 (-
52 (68
II kot/ IIil kii J
- 64 (-) (WB & IF)
,/94) -§
45) -§
!/52)
)§
36 (37/103) (WB)
j/131) -§
42 (16/38) 1984 (IF)
32 (12/37) 1985 (IF)
4 (5/128) 1983 (IF)
6 (4/62) 1984
[Refl Date
[30] 1983-84
[31] 1984
[32] 1985
[33]-
[34] 1981-85
[35] 1982-85
[36] 1982-85
[37] 1983-85
[38] 1984-85
[39] 1985
[40] 1985
[41] 1984-85
[42] 1983-84
[42] 1983-84
[43] 1985
[44] 1984
[45] 1981-85
[32] 1981-85
[46] 1983-84
[47] 1980-85
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potential blood donors had a sevenfold greater seroprevalence among blacks than
whites [83]. The HIV seropositives in this sample of voluntary blood donors were
largely (82 percent) in the homosexual transmission mode category [79]. The data
from seroprevalence studies of U.S. IVDU uniformly show at least a two- to fourfold
higher seroprevalence among blacks and Hispanics [14,18,25,27] than among whites.
In New York City [14,18,80], New Jersey [21], San Francisco [27], and Connecti-
cut [25], HIV infection is more prevalent among black and Hispanic IVDU than
among white IVDU in large, non-hospitalized study groups drawn from outpatient
drug treatment programs. This racial/ethnic groupassociation with HIV seropositivity
has not been reported among European IVDU. The increased risk of HIV seropositiv-
ity for black and Hispanic IVDU appearsgreater in the Connecticutsamplethan in the
other groups ofIVDU that have been studied. The Connecticut IVDU studied on entry
to drug treatment programs were mostly white (76 percent) [25]. In New Haven in
1986, 82 percent of the blacks and 40 percent of the Hispanics entering the drug
treatment programs wereseropositive, while only 10 percent ofthe whites entering the
same programs were seropositive [25].
There is no clear explanation for these observations yet. The differences in
prevalence by racial/ethnic group do not simply reflect the racial/ethnic group
distribution ofthe IVDU population at riskfor HIV transmission. Theincreased riskof
HIV acquisition among black and Hispanic IVDU seems likely to be due to more
frequent needle sharing with different individuals among blacks and Hispanics,
possibly because of educational and/or socioeconomic factors. There was only a
minimal suggestion of differences in needle-sharing practices in only one of the
relevant studies, however, in which univariate analysis revealed that more whites (18
percent) than blacks (8 percent) reported using sterile needles at least half the time
[18]. Therefore, it is also possible that racial/ethnic group (or socioeconomic)
differences may be correlated with a higher prevalence ofa behavioral risk factor (i.e.,
specific injection practice) or a pathogenetic cofactor that increases the efficiency of
HIV transmission. Viruses that may act as cofactors for HIV by increasing the
likelihood of a productive infection upon HIV inoculation may be more prevalent
among U.S. blacks and Hispanics. Herpesviruses, such as human cytomegalovirus
(CMV) or Epstein-Barr virus (EBV), or other retroviruses, such as human
T-lymphotropic virus, type 1 (HTLV-I), might be hypothesized to play such a role.
Case clustering (i.e., strictly intra-racial needle sharing) seems unlikely to account for
the association with racial/ethnic group in New Haven based on reports of former
addicts. A genetic predisposition to HIV infection among blacks must be considered,
but may not be a plausibleexplanation, given the high HIV seroprevalence rate among
Hispanics as well. Even before the necessary studies are done to determine the aspect
of the human biology of HIV that is responsible for this phenomenon, it is vital to
target educational efforts to blacks and Hispanics, as well as IVDU ingeneral. The risk
of HIV transmission will begreater when injection equipment is re-used after an initial
use by a member of a higher prevalence IVDU sub-group; i.e., blacks and Hispanics.
MODES OF HIV TRANSMISSION
The likelihood of HIV transmission with each encounter with an infected person
may vary in different kinds of sexual, and non-sexual bloodstream, encounters. In
homosexual/bisexual men, a number of studies have pointed to specific sexual
practices (particularly receptive anal intercourse [81,82]) that increase the risk of
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acquiring HIV. Guidelines for the education and counseling of homosexual/bisexual
men have been based on such studies. Similar information about injection practices
and heterosexual intercourse would be useful in optimizing educational campaigns for
AIDS risk reduction among IVDU, might lead to new strategies in the difficult battle
against drug abuse, and will help to predict the future extent of the spread of HIV
among needle-sharing IVDU and from IVDU to their heterosexual partners.
While little data exist to quantitate relative risks, sexual contact seems a less
common mode of transmission among IVDU than the re-use of HIV-contaminated
injection equipment. One report of stable heterosexual couples in Italy found concor-
dant HIV seropositivity in 58 percent (7/12) of the couples where both were
needle-sharing IVDU, but in only 8 percent (1/12) of the couples where only one
partner was an IVDU [83], suggesting that sexual intercourse was a less efficient
means of HIV transmission than needle sharing. Nevertheless, concern about spread
by heterosexual contact from IVDU to those who do not consider themselves at riskfor
HIV infection is warranted. Forty-eight percent (20/42) of the heterosexual partners
of New York City IVDU with AIDS or ARC were HIV-seropositive [84]. While
male-to-female heterosexual transmission is firmly established and primarily related
to acquisition from IVDU [85] in the U.S., the controversy about the extent (and
relativeefficiency) offemale-to-male sexual transmission of HIV in the U.S. continues
[86-89]. The need for longitudinal studies to compare the incidences, duration of
infectiousness, and course of HIV-related disease among heterosexual couples who
have discordant drug abuse habits (that is, sexual but not needle-sharing contact)
remains acute to assess fully the potential for expansion ofthe epidemic from IVDU to
the non-drug abusing U.S. population.
The role ofspecific injection/needle-sharing practices in the acquisition of HIV by
IVDU is also of public health interest. There is little knowledge about how IVDU
inject drugs, but former addicts report extensive use of "hitters" (person who find a
vessel for injection for a fee without regard for sterile technique), "booting" (rinsing
the last remnants of drug from syringes by drawing blood in and out of the shared
syringe several times), and common "cookers" (from which solubilized drug is drawn
up for "booting" into many different individuals' syringes, allowing admixtureofblood
from different individuals in the "cooker"). Such descriptions suggest that some
injection practices may be highly efficient at transmitting HIV, but the descriptions
are not sufficient to reveal the real environment in which HIV is spreading in the
isolated world of IVDU. It remains possible that specific injection practices help
determine which needle-sharing IVDU acquire HIV.
Needle sharing is deeply embedded in the drug abuse subculture and seems to serve
both social and economic purposes. Both "works" (syringe, needle, and other equip-
ment) and drugs are often shared between "running buddies" who cooperate to obtain
drugs. Refusal to share "works" and/or drugs might be interpreted in that context as
an attack on the only bond of friendship in a world dominated by mistrust, fear, and
violence. It is common for IVDU to rent works at the time ofdrug purchase, especially
in those states with criminal penalties for drug paraphernalia possession. The works
may also be shared because withdrawal symptoms, apathy, or inconvenience limit the
attempts to get an available sterile needle. There is also an economic variable, as
needles may not be available or affordable for purchase. Similar reasons for needle
sharing have been reported from many locations, including areas with low HIV
seroprevalence such as Dallas [90] and Sydney [61].
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Several studies have shown that almost all the IVDU interviewed in 1984-86 in New
York City, New Jersey, and Connecticut do know that needle sharing and sexual
intercourse are the modes of acquisition of AIDS [91-94]. There is also considerable
reported behavioral change: about 60 percent ofthe respondents oftwo New York City
studies [91,92] attempted to reduce hazardous injection practices by stopping or
decreasing needle sharing, stopping IV drug use, or attempting to sterilize needles. In
another study in New Jersey, almost half said they were entering drug treatment
because they were afraid of AIDS [93]. Ethnographic evidence from New York City
suggests that IVDU may be attempting to protect themselves from HIV infection: the
ilicit market for sterile needles has increased, some drug dealers have distributed
"free" works as a marketing technique, and some fraudulent street sale of used,
re-sealed needles as new has occurred [95,96]. Among those being admitted to drug
treatment programs in New Haven in 1986 [94], most (65 percent) had shared needles;
most said they shared with friends and acquaintances, and very few reported sharing
with strangers (as has been noted in Dallas [90]). Almost all ofthe New Haven sample
(97 percent) attempted to clean shared needles, albeit probably ineffectively by rinsing
with tap water [94]. In San Francisco, almost all the IVDU interviewed cleaned
needles prior to injection, but less than 20 percent of these used methods effective for
HIV decontamination, such as boiling or alcohol [27]. In that study, a protective effect
of needle cleaning on HIV seropositivity was not seen [27]. The public health policy
implications of this recognition of the modes of transmission of HIV and possible
attempts to interrupt such transmission by IVDU will be discussed below.
NATURAL HISTORY OF HIV INFECTION IN IVDU
A better understanding of why AIDS (or other clinical manifestations) develops
within a few years in some HIV-infected persons and not others is necessary to estimate
the full impact of the HIV epidemic. The extent of the future spread of the HIV
epidemic depends largely on a complex interplay of still unknown parameters-the
degree and duration of infectiousness and life span of HIV-infected persons [97]. The
clinical outcome after infection with HIV may be anywhere along a continuum of
increasing immunodeficiency that has been arbitrarily divided into asymptomatic
infection, generalized lymphadenopathy, AIDS-related complex (ARC), and AIDS
[98-100]. (Neurologic disease also occurs but often is unassociated with manifesta-
tions of immunodeficiency and may be due to different pathogenic processes.) A copy
of HIV genetic material is presumed to remain integrated in the genome of infected
human cells for life. The "incubation period" from time of infection to onset of disease
and the percentage of infected persons that ultimately develop illness remain
undefined, largely because of the limited observation period (since 1981). Both
parameters have increased with the length of observation, however. It is hypothesized
that the clinical manifestations of HIV infection are due to progressive depletion ofthe
major cell type that supports cytopathic HIV replication-the T-helper lymphocyte.
While many large cohorts of homosexual/bisexual males have been studied to
determine the natural history of HIV infection, only a few groups of IVDU have been
studied. Small samples, short periods of follow-up, and lack of knowledge of duration
ofinfection for prevalent HIV seropositives limit these data from groups ofIVDU. The
longest follow-up to date-from 1982 to 1985-includes only 29 percent ofa group of
24 New York City IVDU who were HIV-seropositive on entry [101]. Two IVDU from
this group (at least 8.3 percent of the cohort) had developed AIDS by 1985 [101]. A
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larger sample from New York City (166 HIV-seropositives) was followed for a shorter
time (nine months in 1984-85) with a 4 percent annualized rate (5/166) ofdeveloping
AIDS [16]. While 54 percent of this group initially had normal absolute T-helper
lymphocyte (T4-positive cell) counts, 26 percent of the group had T4-positive cell
counts that decreased to below normal over nine months, suggesting progressive
HIV-related disease [16]. Another group of 36 HIV-seropositive New York City
IVDU followed for one year (1984-85) included 8.3 percent (3/36) who developed
AIDS over that year and 25 percent (9/36) who had generalized lymphadenopathy on
initial presentation [19]. In Geneva [45], 42 HIV-seropositive IVDU were followed for
an average of 28 months after seroconversion with a risk ofdeveloping AIDS of only
0.14 percent; however, 69 percent ofthis group developed generalized lymphadenopa-
thy. Similar data on the high frequency of generalized lymphadenopathy in HIV-
infected IVDU has bpen presented from Edinburgh [35] and is consistent with the
clinical impression and preliminary data gathered in New Haven as well. Data from
homosexual/bisexual cohorts suggest, however, that generalized lymphadenopathy
may not be a stable, long-term outcome after HIV infection; the risk of developing
AIDS continues for up to five years after onset of lymphadenopathy without
decreasing [102].
Markers that are predictive ofHIV-related disease progression, whether or not they
determine the outcome, have been sought in epidemiologic studies. Unexplained oral
candidiasis was often found to be the first manifestation of AIDS, preceding the
development of serious opportunisitic infections more than 50 percent of the time in
previously healthy New York City IVDU [103]. The most strongly predictive markers
for progression defined in homosexual/bisexual cohorts are: decreases in the number of
T-helper lymphocytes [104], decreases in antigen-stimulated lymphocyte proliferation
and gamma-interferon generation [105], and a progressive loss ofantibody to an HIV
virion core protein (anti-group specific antigen [gag, p24] antibody) [44,106,107]. In
one large prospective study, a number of factors were found to predict outcome
independently among the prevalent homosexual/bisexual HIV-seropositives: increased
T-suppressor/cytotoxic cell number, decreased T-helper cell number, reduced amount
ofserum HIV antibody (defined as reactivity in optical density units on a commercial
EIA for HIV), an increased amount of serum CMV antibody (possibly reflecting
recent, active CMV replication), and a history of sexual contact with someone who
developed AIDS [108]. The last factor listed is of interest since it suggests either that
this exposure variable reflects longer-standing HIV infection, that some strain
variation exists in the pathogenicity of HIV, or that another cofactor (such as another
virus) is involved in the pathogenesis ofAIDS.
In vitro studies have also suggested a number ofvariables that might determine the
outcome after HIV infection. Antigen (or mitogen) stimulation of T-helper cells in
vitro enhances the efficiency and productivity ofwhat would otherwise be a latent HIV
infection [109,110]. The transcription oflatent HIV long terminal repeat-linked genes
(that are integrated into the host cell genome) is dramatically increased in vitro after
herpes simplex [111,112], varicella zoster, papillomavirus, or papovavirus [112]
infections. It seems possible that chronically repeated in vivoactivation ofthe immune
system (by other infections or by the allogeneic stimulation of needle sharing) may
improve the chances ofestablishing an HIV infection after exposure and also shorten
the length ofthe period from HIV acquisition to disease onset. Another possible factor
in the pathogenesis ofHIV-related disease in IVDU is thepotentially immunosuppres-
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sive effect ofopiates. Opiates impair in vitro T-cell mitogen responsiveness [113,114],
an effect which is reversed by naloxone [113].
Given such epidemiologic and biologic data, the finding that continued IV drug
injection was associated with greater decreases in T-helper lymphocyte counts in a
cohort of IVDU followed over nine months [16] strongly suggests that disease
progression wasduetooneormoreofa numberofpossiblefactors: immunosuppression
from the drugs injected, antigenic stimulation from other injected microbes or other
individuals' cells, reinfection with HIV ofthesameordifferent strain, orinfection with
another virus that may activate latent HIV (or increase the productivity of an HIV
infection). Further studies of HIV-infected IVDU may help to separate some ofthese
possible factors and expand knowledge ofthe pathogenesis ofAIDS.
When HIV infection has progressed to AIDS, IVDU may have a worse prognosis
than persons in other HIV transmission categories. IVDU with AIDS rarely present
with Kaposi's sarcoma and usually develop multiple opportunistic infections; survival
figures reflect the fact that IVDU have more rapidly fatal manifestations ofimmuno-
deficiency. Whether these differences are due to different pathogenetic processes
resulting in more severe immunosuppression after parenteral rather than rectal
mucosal inoculation of HIV remains conjectural. Much of the apparent excess
morbidity among HIV-infected IVDU (compared to persons in other HIV transmis-
sion categories) may be related to socioeconomic rather than biologicvariables; health
knowledgeand access to health services areless thanoptimal among IVDU. Inorder to
explain the much lower prevalence of Kaposi's sarcoma cases among AIDS patients
outside of the homosexual/bisexual HIV transmission mode category, it has been
hypothesized that homosexual/bisexual men are morelikelythan personsinother HIV
transmission mode categories to be exposed to another cofactor (possibly an unidenti-
fied virus transmitted by semen) that leads to Kaposi's sarcoma [104].
The increases in premature mortality related to AIDS are already considerable in
New York City and most marked among blacks and Hispanics [115]. In addition to
increases in deaths due to AIDS among IVDU, a large increase in narcotic-related
deaths due to pneumonia has been seen in New York City, while other causes of
mortality in IVDU (i.e., overdose, cirrhosis, and so on) have not changed [115].
Infection with Mycobacterium tuberculosis is also a growing problem among HIV-
infected persons [72,116-119], particularly among urban IVDU. In 1985, the national
average annual decline in tuberculosis morbidity (expected to be about 5 percent) did
not occur [116], and in some areas, such as Florida and Connecticut, the incidence
increased [117,118]. Severeand unusualpresentationsofMycobacterium tuberculosis
infection may precede the diagnosis of AIDS among those at risk for HIV infection,
although the response to standard therapy appears good [119]. IVDU are also prone to
acquire other infections, such as endocarditis and soft-tissue infections. Two studies
have noted an association between HIV seropositivity among IVDU and such
non-opportunistic infections [29,120]. It seems likely that this association represents
selection bias toward those whose more intensive drug injection habits lead to both
greater HIV exposure and other injection-related infections, but HIV-induced immu-
nosuppression may predispose to such non-opportunistic infections. Bacteria that are
prominent pathogens in B-cell deficiency states, such as Hemophilus influenzae and
Streptococcus pneumoniae, have been described as etiologic agents of pneumonia
among HIV-infected persons [121], and such pathogens might be expected to be
successful opportunists at other body sites in HIV-infected IVDU as well. Thrombocy-
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topenia often precedes other manifestations of HIV infection and may have a different
pathophysiology in IVDU than in HIV-infected homosexual/bisexual men [122]. The
finding of antibody to HTLV-I (and HTLV-II) among stored sera from New York
City IVDU [14] raises the specter of retrovirus-related malignancy (and possibly as
yet undefined interactions with HIV) among IVDU. The full impact on the public
health of the epidemic of HIV infection among IVDU cannot yet be assessed, but it
clearly will not be limited to what is currently the Centers for Disease Control (CDC)
case definition ofAIDS.
PUBLIC HEALTH POLICY IMPLICATIONS
The public health is threatened by this developing epidemic to an extent that is
unsurpassed in recent history. The U.S. Public Health Service (USPHS) projects that
by 1991 approximately 270,000 individuals will have developed AIDS, with projected
medical care costs of$16 billion [123]. Ifpresent trends continue, many of these cases
will occur among thesocially disadvantaged, and the burden in social disorganization
and economic cost to thepublictreasury will bestaggering. More research is necessary
to estimate accurately the full extent of the future problem and to develop optimal
strategies for intervention at the level of both transmission and disease progression.
Planning to allow IVDU greater access to medical, nursing, and social service
resources must begin. The major immediate need, however, is for action to stop this
epidemic by eliminating drug injection or, at the least, stopping IVDU from re-using
potentially HIV-contaminated injection equipment.
The most effective public health response at this time would be primary prevention
ofdrug abuse. Adolescents at thejunior and senior high school level are the most likely
tobeginexperimentation andregular useofaddictive drugs; campaigns directed at this
age group might be effectively increased [124]. It may well be beneficial to link the
"war ondrugs" with the "war on AIDS." Discussions ofthe realities ofdrug addiction
and AIDS withyoungpeoplemightdiscourage experimentation. Indeed, one survey of
Connecticut senior high school students found that the students knew very little about
AIDS anddrug abuse [2]. The students wereparticularly unaware ofthe transmission
ofAIDS to the children and heterosexual partners ofdrug abusers [2]. In one Italian
community, a striking fall in admissions for acute viral hepatitis and an increase in
applicants for methadone maintenance drug treatment has been recorded in 1985-86
[125]. Since acute viral hepatitis is usually acquired during the first 18-24 months of
heroin abuse, this suggests the possibility of fewer new IVDU in that community in
response to a fear ofAIDS [125].
The approach to those who are already addicted is more problematic, but the goal
should be to stop IVDU from injecting drugs. Current drug addiction treatment
programs are limited in capacity and not always successful at eliminating IV drug
injection. It is common fordrug addiction to take a chronically relapsing and remitting
course with successive treatments followed by longer remissions [126]. Indeed,
injection drug use may not cease while an addict is in treatment. Thus, simply
expanding U.S. drug treatment programs (largely chronic outpatient methadone
maintenance with extensive counseling/rehabilitation services) to accommodate all
applicants immediately (instead of the current one- to six-month waiting periods for
program entry in many cities) may not decrease transmission of HIV among IVDU.
Decreasing drug injection, however, or stopping for a time might be expected to
interrupt the natural history of HIV infection and potentially prolong the time to (or
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prevent the development of) illness by any one of a number of potential mechanisms
discussed above. These hypotheses are currently under study in New Haven by
comparing the incidence and natural historyof HIV infection in IVDU who have been
stable on methadone maintenance with those who have failed treatment.
If drug injection by IVDU cannot be stopped, a major effort to eliminate needle
sharing may be the most effective way to halt this epidemic. In Amsterdam, a needle
exchange program that allows IVDU toobtain sterilesyringes and needles in return for
used ones has been in operation for about two years. The goal is to stop needle sharing
by making sterile needles readily available, but an evaluation of the program's
effectiveness toward that end has not yet been published. Britain is also setting up a
small pilot needleexchangeprogram, and both Franceand Switzerland recentlymoved
to allow the over-the-counter sale ofsyringes and needles in pharmacies [127]. It is of
interest that syringes have been available in Italian pharmacies without prescription
for some years, and HIV seroprevalence has risen swiftly among Italian IVDU (refer
to Table 3).
In the U.S., there have been suggestions for programs akin to the Dutch attempts to
providesterileneedlesand syringes to IVDU. Thepossibilityoffosteringdrug abuseby
making it easier to acquire injection paraphernalia and the lack ofproofthat a needle
exchange program would alter the pervasive needle-sharing behaviors of IVDU has
prevented these proposals from gaining favor. The social, legal, educational, and
financial impediments to supplying sterile needles to IVDU in the U.S. are consider-
able, and evidence of the effectiveness of existing needle exchange programs seems
necessary before such a plan can be seriously considered.
State legislative bodies, however, might consider a different approach to decreasing
needle sharing without awaiting further data. The criminal penalties for possession of
drug injection paraphernalia might be adjusted to reflect more accurately society's
current interest. It might be reasonable to attempt to enforce more stringent penalties
for possession ofused (or re-sealed) needles or multiple needles than the possession of
one sterile needle. The possibility of decriminalization of injection equipment posses-
sion might alsobediscussed as an alternative toproviding sterile needles thatwould not
make it easier for young persons to begin to abuse IV drugs. One major motivation for
needle sharing might be removed by eliminating the criminal penalty for addicts to
carry their personal "works."-
The HIV epidemic among IVDU in the U.S. might be interrupted immediately,
however, by encouraging the existing trend among IVDU to clean shared needles, as
described above. While most IVDU do not use methods known to inactivate HIV,
effective methods could be taught. Boiling or using alcohol are impractical methods
that IVDU have not accepted; the former is impossible in the addicts' environment,
and some former addicts report that alcohol destroys the lubricant in disposable
syringe plungers, making the syringe unusable [personal communication]. Careful
virologic studies ofalternative needle-cleaning methods have not yet been reported. In
San Francisco and other locations, however, IVDU have been more accepting ofusing
household bleach (sodium hypochlorite) to clean needles. An innovative marketing
approach has clearly helped to get the message across (Fig. 1). Pocket-sized, refillable
bottles with cartoon instructions on use can be introduced into the needle-sharing
setting much less awkwardly than an IVDU can refuse to share works with a "running
buddy." As the developers of the concept say, the "bleach bottle" is the "moral
equivalent of the condom." Like the condom, this approach to risk reduction requires
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Location/Group
Innsbruck, Austria
Prisoners
Milan, Italy
Meth. Maint. & Hosp.
Residential treatment
Hosp.
Rome, Italy
Meth. Maint.
Padua, Italy
Hepatitis study
Bari, Italy
Hepatitis study
Toulouse, France
Tours, France
Hosp.
Paris, France
Prisoners
Athens, Greece
Prisoners
Belgrade, Yugoslavia
Zagreb, Yugoslavia
Sydney, Australia
Thailand
Hong Kong
Tamilnadu State, India
Prostitutes (?IVDU)
aRefer to footnotes ofTable 1.
TABLE 3
HIV Seroprevalence Among IVDU'
% EIA + (No.) % Confirmed + (No.)
30 (212/716)
7 1979
22 1982
60 1985
21 (79/382)
0 (0/129) 1978-79
6 (4/68) 1980
10 (6/58) 1981
15 (7/47) 1982
31(15/49)1983
53 (18/34) 1984
76 (45/59) 1985
51(205/402)
45 (111/244)
6 (9/142)
2 (2/100)
0 (0/99)
0 (0/508)
0 (0/14)
5 (50/1,025)
44 (15/34) (WB & IP)
29 (61/209) 1985
0 1979-80 (IF)
53 (33/62 1984-5
7 1981 (IF)
20 (26/128) (IF)
28 (58/207) (IF)
16 (60/382) (WB)
0 1978-79
1.4 1981
15 1983
43 1985
0 (0/52) 1982-83 (WB)
15 (10/40) [sic] 1984
17 (21/125) 1985
64 (71/113) (WB)
2 (6/288) (WB)
45 (10/22 EIA+'s) (WB)
6 (9/142) (WB)
3 (30/1,025) (WB)
[Ref] Date
[48] 1985
[49] 1979-85
[49] 1979-85
[50] 1978-85
[51] 1985
[52] 1985
[53] 1978-85
[54] 1978-85
[55] 1985
[56] 1982-85
[57] 1985
[58]-
[59] 1985
[60]-
[61]-
[62] 1985
[63] 1985
[64] 1987
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You can stopAIDS.
1 2
Bleoch e k a> Woter
Flush 2X Flush 2X
Do not squirt used bleoch bock into bottle.
Keep out of reach of children
For more informotion call 863-AIDS.
S S S S S S S .53
FIG. 1. The "bleach bottle" label. One-ounce, refillable bottles of household
bleach (sodium hypochlorite) have been widely distributed among San Francisco
IVDU by indigenous addict-educators for de-contaminating shared injection
equipment of HIV prior to drug injection.
absolute consistency in order to be effective. There is also the possibility that sharing of
other injection paraphernalia (i.e., the "cooker") might make futile the effects of
needle cleaning.
The use ofindigenous addict-educators (largely former and present addicts) may be
the best available approach to disseminate needle-cleaning and other health educa-
tional material to the isolated, stigmatized, untrusting IVDU subculture. The undeter-
mined proportion of IVDU who are not in drug treatment programs will probably not
bereached by anyother means. The "bleach bottle" was introduced by street-wise field
workers in San Francisco, and a similar approach to IVDU education has been ongoing
in New York City [92] and New Jersey [93].
It is now crucial to offer individualized, in-depth counseling about HIV infection to
IVDU in all drug addiction treatment programs in the U.S. Voluntary, confidential
HIV screening may be a useful adjunct to such an effort. Whether an individual
IVDU's knowledge of an HIV antibody test result will be conducive to a socially
beneficial behavioral change remains at issue, however. For example, a seropositive
IVDU may decide that there is nothing to lose by continuing drug injection and needle
sharing. An IVDU found to be seronegative may take false assurance that his
particular practices (i.e., needle sharing only with friends or cleaning needles with tap
water, for example) are effectively protecting him or her from HIV infection and
continue such clearly dangerous practices. A number ofstudies (see above) do suggest
that IVDU are capable of, and interested in, decreasing their risk of HIV infection.
The most effective way to motivate IVDU to reduce their riskof HIV infection and its
progression to AIDS remains to be determined. Screening all pregnant IVDU (and
women whose sexual partners are IVDU) for HIV seropositivity also seems useful for
the psychological well-being ofthe mother and the health ofthe expected infant. It also
seems reasonable to screen clients from known HIV transmission categories in
long-term psychiatric institutions for HIV seropositivity and potentially cohort
together theseropositives ifthere is any riskofsexual or needle-sharing contact among
such clients.
A much larger effort to educate the general public as well as IVDU about
HIV-related health issues is also needed. Until now, AIDS educational efforts have
been aimed at the largely white, well-educated, homosexual/bisexual community. The
racial/ethnic groups at greatest risk for HIV infection and AIDS must be reached with
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the message that needle sharing and heterosexual (as well as homosexual) activity with
an IVDU carry a riskofacquiring HIV. In order toavoid fueling ugly bigotry, much of
which has already been directed toward homosexual/bisexual men, it is necessary to
inform the public fully and explicitly in regard to the scientific certainties about the
lack of HIV transmission by means other than unprotected sexual and bloodstream
contact.
Limitation of the spread of HIV within IVDU and to their sexual contacts and
children ought to be a high social priority. Historically, drug abuse has, however, been
a persistent and perplexing problem for our society. As the International Working
Group on AIDS in IVDU emphasized in June 1986, "the extraordinary nature ofthis
epidemic demands comprehensive and creative responses" [128]. All pragmatic
measures, no matter how controversial, should be considered in mobilizing against this
threat. Protection of the public health from this "social" disease can be effected
through sociocultural, as well as immuno-pharmacologic, advances. Indeed, as
Mathilde Krim has stated in a more general context, how societies "will deal with the
threat of AIDS will measure to what extent they have the right to call themselves
civilized" [129].
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